About Verona Pharma (NASDAQ:VRNA)
Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and IIa clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease and cystic fibrosis. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:VRNA
CUSIPN/A
Phone44-20-3283-4200
Debt
Debt-to-Equity RatioN/A
Current Ratio10.14%
Quick Ratio10.14%
Price-To-Earnings
Trailing P/E Ratio-6.89
Forward P/E Ratio-5.89
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$7.84 per share
Price / Book2.12
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees15
Outstanding Shares13,130,000
Verona Pharma (NASDAQ:VRNA) Frequently Asked Questions
What is Verona Pharma's stock symbol?
Verona Pharma trades on the NASDAQ under the ticker symbol "VRNA."
How were Verona Pharma's earnings last quarter?
Verona Pharma (NASDAQ:VRNA) posted its earnings results on Tuesday, February, 27th. The company reported ($0.64) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.83) by $0.19. View Verona Pharma's Earnings History.
What price target have analysts set for VRNA?
5 Wall Street analysts have issued 1 year price targets for Verona Pharma's shares. Their forecasts range from $25.00 to $55.00. On average, they expect Verona Pharma's share price to reach $34.60 in the next year. View Analyst Ratings for Verona Pharma.
Who are some of Verona Pharma's key competitors?
Some companies that are related to Verona Pharma include Synergy Pharmaceuticals (SGYP), Depomed (DEPO), Syros Pharmaceuticals (SYRS), Cara Therapeutics (CARA), Albireo Pharma (ALBO), Kala Pharmaceuticals (KALA), Corium International (CORI), Cytokinetics (CYTK), Mersana Therapeutics (MRSN), Corbus Pharmaceuticals (CRBP), GTX (GTXI), Dermira (DERM), Clearside Biomedical (CLSD), Strongbridge Biopharma (SBBP), Paratek Pharmaceuticals (PRTK), Merus (MRUS), Kadmon (KDMN) and Catalyst Biosciences (CBIO).
Who are Verona Pharma's key executives?
Verona Pharma's management team includes the folowing people:
- Dr. Jan-Anders Karlsson, Chief Exec. Officer & Exec. Director (Age 63)
- Mr. Piers John Morgan MA, ACA, Chief Financial Officer (Age 52)
- Ms. Claire Louise Poll, Legal Counsel (Age 51)
- Dr. Peter Spargo Ph.D., Sr. VP of CMC (Age 56)
- Dr. Kenneth Newman, Chief Medical Officer (Age 60)
When did Verona Pharma IPO?
(VRNA) raised $61 million in an initial public offering (IPO) on Thursday, April 27th 2017. The company issued 4,500,000 shares at a price of $13.49 per share. Jefferies and Stifel served as the underwriters for the IPO and Wedbush PacGrow and SunTrust Robinson Humphrey were co-managers.
Has Verona Pharma been receiving favorable news coverage?
News coverage about VRNA stock has been trending somewhat negative this week, Accern Sentiment Analysis reports. The research group identifies negative and positive media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Verona Pharma earned a media sentiment score of -0.06 on Accern's scale. They also gave news coverage about the company an impact score of 45.64 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.
How do I buy shares of Verona Pharma?
Shares of VRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Verona Pharma's stock price today?
One share of VRNA stock can currently be purchased for approximately $16.61.
How big of a company is Verona Pharma?
Verona Pharma has a market capitalization of $218.04 million. The company earns $-26,410,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis. Verona Pharma employs 15 workers across the globe.
How can I contact Verona Pharma?
Verona Pharma's mailing address is 3 MORE LONDON RIVERSIDE, LONDON X0, SE1 2RE. The company can be reached via phone at 44-20-3283-4200 or via email at [email protected]
MarketBeat Community Rating for Verona Pharma (VRNA)
MarketBeat's community ratings are surveys of what our community members think about Verona Pharma and other stocks. Vote "Outperform" if you believe VRNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
Verona Pharma (NASDAQ:VRNA) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
5 Wall Street analysts have issued ratings and price targets for Verona Pharma in the last 12 months. Their average twelve-month price target is $34.60, suggesting that the stock has a possible upside of 108.31%. The high price target for VRNA is $55.00 and the low price target for VRNA is $25.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $34.60 | $28.00 | $26.75 | $26.75 |
| Price Target Upside: | 108.31% upside | 86.67% upside | 135.06% upside | 60.56% upside |
Verona Pharma (NASDAQ:VRNA) Consensus Price Target History
Verona Pharma (NASDAQ:VRNA) Analyst Ratings History
Show:
(Data available from 4/23/2016 forward)
Verona Pharma (NASDAQ:VRNA) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Verona Pharma (NASDAQ VRNA) Insider Trading and Institutional Ownership History
Institutional Ownership Percentage: 44.23%
Verona Pharma (NASDAQ VRNA) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
(Data available from 1/1/2013 forward)
Verona Pharma (NASDAQ VRNA) News Headlines
| Source: |
|
Verona Pharma (NASDAQ:VRNA) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Verona Pharma (NASDAQ:VRNA) Income Statement, Balance Sheet and Cash Flow Statement
Verona Pharma (NASDAQ VRNA) Stock Chart for Monday, April, 23, 2018
Loading chart…
